Mucocort, business supported by Umeå Biotech Incubator, will initiate a clinical trial of their intraoral patch. The clinical trial will be conducted in collaboration with Oral Care AB and the production is managed by Aurena Laboratories AB.
Mucocort, business supported by Umeå Biotech Incubator, will initiate a clinical trial of their intraoral patch. The clinical trial will be conducted in collaboration with Oral Care AB and the production is managed by Aurena Laboratories AB.

Press release -

Mucocort initiates clinical trial of innovative patch for aphthous stomatitis

Mucocort AB has received approval from the Swedish Medical Products Agency and the Ethics Review Board to commence a clinical trial of an intraoral patch (M045A) for the treatment of aphthous stomatitis, a condition affecting approximately 2 percent of the population and causing frequent mouth ulcers with significant pain for affected patients.
"We are pleased to soon be ready to welcome our first patient to the trial," says Jean Lycke, project manager for Mucocort AB.

Mucocort's treatment consists of a self-absorbing patch (M045A), classified under the MDR as a Class II product. Through extensive research and development, this patch has demonstrated the potential for immediate pain relief and promoting healing processes in patients with aphthous stomatitis.

The clinical trial will be conducted in collaboration with Oral Care AB, an established private dental clinic chain also focused on research. Production of the patch is managed by Aurena Laboratories AB, a family-owned company that is also a strategic partner for marketing, sales, and international launch.

Estimated time is six to nine months
Mucocort is pleased that both the clinical trial and future production are taking place in Sweden.
"We look forward to collaborating with Oral Care, and our relationship with Aurena is excellent. Both organizations share our focus on sustainable solutions and improved care. The collaboration with Umeå Biotech Incubator has also been a significant part of our success in developing our patch," says Jean Lycke.

The estimated duration of the clinical trial is six to nine months. After completion of the study, results will be evaluated to assess treatment effectiveness. The primary endpoint is pain relief, and the study will also include quality-of-life assessments using EQ-5D/OHIP14.

For more information, please contact:
Jean Lycke, Project Manager, Mucocort AB
Phone: +46 702 771 511
Email: jl@emerentiagruppen.com

About Mucocort AB
Mucocort is a company within the medtech sector, focusing on developing innovative medical solutions to improve treatment and quality of life for patients worldwide. Through partnerships with like-minded visionaries, Mucocort AB aims to offer more effective treatments and solutions for various medical needs within mucosal treatment primarily.

Topics

Categories

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Contacts

Tomas Ruuth

Tomas Ruuth

Press contact Head of PR & Communications PR & Communications 072-4024697 www.ubi.se

Related media

Download images for media use

Related content

Mucocort secures European patent and strengthens collaboration with Aurena Laboratories

Mucocort secures European patent and strengthens collaboration with Aurena Laboratories

Swedish MedTech company Mucocort plans to launch a mucosal self-absorbing patch for pain relief in people suffering from aphthous stomatitis (mouth ulcers). The interest in Mucocort patch technology has increased after the approval of a European patent. Further, the Mucocort AB minority stakeholder Aurena Laboratories steps up with additional capital and increases its ownership.

The Mucocort team from the left: Mats Jontell, Olle Isaksson, Thomas Hedner och Jean Lycke.

Mucocort signs new production deal for pain-relieving mouth ulcer treatment

Mucocort AB is a Swedish company that has developed a unique self-absorbing pain relief patch for people suffering from recurrent mouth ulcers - aphthous stomatitis. The company has now signed a production agreement with medical technology company Aurena Laboratories AB, which also becomes a stakeholder in Mucocort.

Mucocort AB is developing an innovative mucoadhesive "patch" for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases. The Chinese patent secures Mucocort's technology in one of the largest markets globally.

Mucocort receives additional patent approval for its innovative patch technology

The Swedish MedTech company Mucocort AB has been granted a patent in China for its innovative product/technology, which has previously been approved under the European Patent System (EPC). Mucocort develops a mucoadhesive "patch" for mouth ulcers (aphthous stomatitis), one of the most common oral mucosal diseases.

We grow ideas that can change the world

Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.

Umeå Biotech Incubator
Umeå Biotech Incubator

Tvistevägen 48C
907 36 Umeå
Sweden

ubi.se
Umeå Biotech Incubator Enter your email address to follow Umeå Biotech Incubator

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Umeå Biotech Incubator Check your inbox

Email sent to __email__. Click the link there to follow Umeå Biotech Incubator.

Okay